AU2020271123A1 - FLT3-specific chimeric antigen receptors and methods of using the same - Google Patents

Info

Publication number

AU2020271123A1

AU2020271123A1 AU2020271123A AU2020271123A AU2020271123A1 AU 2020271123 A1 AU2020271123 A1 AU 2020271123A1 AU 2020271123 A AU2020271123 A AU 2020271123A AU 2020271123 A AU2020271123 A AU 2020271123A AU 2020271123 A1 AU2020271123 A1 AU 2020271123A1

Authority

AU

Australia

Prior art keywords

antigen

car

nucleic acid

cell

sequence encoding

Prior art date

2019-04-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 605
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 title claims abstract description 227
• 238000000034 method Methods 0.000 title claims abstract description 89
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 title claims abstract description 13
• 239000000427 antigen Substances 0.000 claims abstract description 646
• 108091007433 antigens Proteins 0.000 claims abstract description 644
• 102000036639 antigens Human genes 0.000 claims abstract description 644
• 210000004027 cell Anatomy 0.000 claims abstract description 314
• 230000027455 binding Effects 0.000 claims abstract description 313
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 273
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 271
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 271
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 132
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 125
• 201000011510 cancer Diseases 0.000 claims abstract description 116
• 230000003834 intracellular effect Effects 0.000 claims abstract description 54
• 230000005754 cellular signaling Effects 0.000 claims abstract description 51
• 239000013604 expression vector Substances 0.000 claims abstract description 43
• 210000002865 immune cell Anatomy 0.000 claims description 99
• 239000000203 mixture Substances 0.000 claims description 74
• 239000013598 vector Substances 0.000 claims description 67
• 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 37
• 102000010449 Folate receptor beta Human genes 0.000 claims description 36
• 108050001930 Folate receptor beta Proteins 0.000 claims description 36
• 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims description 35
• 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 claims description 35
• 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims description 34
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 33
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 33
• 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 32
• 102100022748 Wilms tumor protein Human genes 0.000 claims description 31
• 101710127857 Wilms tumor protein Proteins 0.000 claims description 30
• 101710145802 Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims description 29
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
• 238000011282 treatment Methods 0.000 claims description 22
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 20
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 19
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 19
• 125000006850 spacer group Chemical group 0.000 claims description 19
• 239000013603 viral vector Substances 0.000 claims description 19
• 108010058905 CD44v6 antigen Proteins 0.000 claims description 18
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 17
• 102100036230 U5 small nuclear ribonucleoprotein 200 kDa helicase Human genes 0.000 claims description 17
• 239000003937 drug carrier Substances 0.000 claims description 17
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 16
• 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 16
• 101710119213 U5 small nuclear ribonucleoprotein 200 kDa helicase Proteins 0.000 claims description 16
• 230000000139 costimulatory effect Effects 0.000 claims description 16
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 15
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 15
• 101710109637 Antigen 43 Proteins 0.000 claims description 14
• 102100034608 Angiopoietin-2 Human genes 0.000 claims description 13
• 108010048036 Angiopoietin-2 Proteins 0.000 claims description 13
• 108010029485 Protein Isoforms Proteins 0.000 claims description 13
• 102000001708 Protein Isoforms Human genes 0.000 claims description 13
• SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 12
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 9
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 9
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
• 210000000822 natural killer cell Anatomy 0.000 claims description 7
• 108060003951 Immunoglobulin Proteins 0.000 claims description 5
• 102000018358 immunoglobulin Human genes 0.000 claims description 5
• 230000001177 retroviral effect Effects 0.000 claims description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
• 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims 6
• 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims 6
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 6
• 101150013553 CD40 gene Proteins 0.000 claims 3
• 102100035793 CD83 antigen Human genes 0.000 claims 3
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 3
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
• 102000009490 IgG Receptors Human genes 0.000 claims 3
• 108010073807 IgG Receptors Proteins 0.000 claims 3
• 102100025390 Integrin beta-2 Human genes 0.000 claims 3
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 3
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 3
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 3
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 3
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
• 102000003675 cytokine receptors Human genes 0.000 claims 3
• 108010057085 cytokine receptors Proteins 0.000 claims 3
• 102000006495 integrins Human genes 0.000 claims 3
• 108010044426 integrins Proteins 0.000 claims 3
• 239000003446 ligand Substances 0.000 claims 3
• 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• 230000000973 chemotherapeutic effect Effects 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 230000006798 recombination Effects 0.000 claims 1
• 238000005215 recombination Methods 0.000 claims 1
• 150000003384 small molecules Chemical class 0.000 claims 1
• 241000124008 Mammalia Species 0.000 abstract description 42
• 238000003259 recombinant expression Methods 0.000 abstract description 37
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
• 230000002062 proliferating effect Effects 0.000 abstract description 10
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 211
• 239000000463 material Substances 0.000 description 47
• 150000001413 amino acids Chemical class 0.000 description 44
• 235000001014 amino acid Nutrition 0.000 description 38
• 125000003729 nucleotide group Chemical group 0.000 description 35
• 108090000623 proteins and genes Proteins 0.000 description 35
• 239000002773 nucleotide Substances 0.000 description 33
• -1 e.g. Proteins 0.000 description 26
• 230000014509 gene expression Effects 0.000 description 20
• 125000005647 linker group Chemical group 0.000 description 20
• 241000282414 Homo sapiens Species 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 201000010099 disease Diseases 0.000 description 15
• 238000009472 formulation Methods 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 description 13
• 102000004196 processed proteins & peptides Human genes 0.000 description 13
• 102100032912 CD44 antigen Human genes 0.000 description 12
• 108091016585 CD44 antigen Proteins 0.000 description 11
• 229920001184 polypeptide Polymers 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 230000008685 targeting Effects 0.000 description 11
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 10
• 239000012634 fragment Substances 0.000 description 10
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 9
• 102000000588 Interleukin-2 Human genes 0.000 description 9
• 108010002350 Interleukin-2 Proteins 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 102100021335 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Human genes 0.000 description 8
• 101710168202 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 Proteins 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 108010004729 Phycoerythrin Proteins 0.000 description 8
• 235000014113 dietary fatty acids Nutrition 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 239000000194 fatty acid Substances 0.000 description 8
• 229930195729 fatty acid Natural products 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 238000013519 translation Methods 0.000 description 8
• 102100022749 Aminopeptidase N Human genes 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 239000003755 preservative agent Substances 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 238000010361 transduction Methods 0.000 description 7
• 108050008264 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 6
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 239000003599 detergent Substances 0.000 description 6
• 230000000694 effects Effects 0.000 description 6
• 230000004068 intracellular signaling Effects 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 230000026683 transduction Effects 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 101710148652 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 description 5
• 108020004705 Codon Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 5
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 5
• 102100039564 Leukosialin Human genes 0.000 description 5
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 229910052727 yttrium Inorganic materials 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 101710165436 Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000006172 buffering agent Substances 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 238000003501 co-culture Methods 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 150000004665 fatty acids Chemical class 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 3
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 108010049990 CD13 Antigens Proteins 0.000 description 3
• 101150031358 COLEC10 gene Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 3
• 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 3
• 101710123866 Interleukin-3 receptor subunit alpha Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• 229930182816 L-glutamine Natural products 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 3
• 108010005832 Leukosialin Proteins 0.000 description 3
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
• 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 125000003118 aryl group Chemical group 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000010586 diagram Methods 0.000 description 3
• 210000003162 effector t lymphocyte Anatomy 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 238000005457 optimization Methods 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 108091033319 polynucleotide Proteins 0.000 description 3
• 102000040430 polynucleotide Human genes 0.000 description 3
• 239000002157 polynucleotide Substances 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
• XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 101710099461 Aminopeptidase N Proteins 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 101710187595 B-cell receptor CD22 Proteins 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 2
• 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 2
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
• 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 102100039064 Interleukin-3 Human genes 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102100040120 Prominin-1 Human genes 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 229910052770 Uranium Inorganic materials 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 2
• 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 2
• 230000003432 anti-folate effect Effects 0.000 description 2
• 229940127074 antifolate Drugs 0.000 description 2
• 239000013602 bacteriophage vector Substances 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 239000004052 folic acid antagonist Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940076264 interleukin-3 Drugs 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000012153 long-term therapy Methods 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 239000008180 pharmaceutical surfactant Substances 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 239000011819 refractory material Substances 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000000344 soap Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• QFQYGJMNIDGZSG-YFKPBYRVSA-N (2r)-3-(acetamidomethylsulfanyl)-2-azaniumylpropanoate Chemical compound CC(=O)NCSC[C@H]([NH3+])C([O-])=O QFQYGJMNIDGZSG-YFKPBYRVSA-N 0.000 description 1
• BFNDLDRNJFLIKE-ROLXFIACSA-N (2s)-2,6-diamino-6-hydroxyhexanoic acid Chemical compound NC(O)CCC[C@H](N)C(O)=O BFNDLDRNJFLIKE-ROLXFIACSA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• DWKNTLVYZNGBTJ-IBGZPJMESA-N (2s)-2-amino-6-(dibenzylamino)hexanoic acid Chemical compound C=1C=CC=CC=1CN(CCCC[C@H](N)C(O)=O)CC1=CC=CC=C1 DWKNTLVYZNGBTJ-IBGZPJMESA-N 0.000 description 1
• FNRJOGDXTIUYDE-ZDUSSCGKSA-N (2s)-2-amino-6-[benzyl(methyl)amino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN(C)CC1=CC=CC=C1 FNRJOGDXTIUYDE-ZDUSSCGKSA-N 0.000 description 1
• WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
• WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
• WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• 108030000394 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferases Proteins 0.000 description 1
• HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
• SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
• YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
• QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
• SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
• MOQVHOPVBREXLY-UHFFFAOYSA-N 3h-dioxol-4-ylmethanol Chemical compound OCC1=COOC1 MOQVHOPVBREXLY-UHFFFAOYSA-N 0.000 description 1
• YXDGRBPZVQPESQ-QMMMGPOBSA-N 4-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C(O)=O)C=C1 YXDGRBPZVQPESQ-QMMMGPOBSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
• 101710185215 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5 Proteins 0.000 description 1
• 101710185185 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6 Proteins 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
• MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
• WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
• ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 108010005465 AC133 Antigen Proteins 0.000 description 1
• 102000005908 AC133 Antigen Human genes 0.000 description 1
• 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
• 108010046643 ADP-ribosyl cyclase 2 Proteins 0.000 description 1
• 101710188695 Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
• 101710188694 Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 241001466804 Carnivora Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102000000311 Cytosine Deaminase Human genes 0.000 description 1
• 108010080611 Cytosine Deaminase Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 102100035233 Furin Human genes 0.000 description 1
• 108090001126 Furin Proteins 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
• 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
• 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
• 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
• 101000659545 Homo sapiens U5 small nuclear ribonucleoprotein 200 kDa helicase Proteins 0.000 description 1
• 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010044023 Ki-1 Antigen Proteins 0.000 description 1
• ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
• JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
• 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 101710147545 Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
• 206010028729 Nasal cavity cancer Diseases 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 102000004459 Nitroreductase Human genes 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 208000010505 Nose Neoplasms Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
• 101710143067 Prominin-1 Proteins 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000032383 Soft tissue cancer Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 241001493546 Suina Species 0.000 description 1
• ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046392 Ureteric cancer Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000000061 acid fraction Substances 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 210000002255 anal canal Anatomy 0.000 description 1
• 201000007696 anal canal cancer Diseases 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 108091006004 biotinylated proteins Proteins 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
• 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 150000001840 cholesterol esters Chemical class 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 210000000959 ear middle Anatomy 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 1
• 102000006815 folate receptor Human genes 0.000 description 1
• 108020005243 folate receptor Proteins 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 210000001822 immobilized cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 201000004962 larynx cancer Diseases 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 210000000713 mesentery Anatomy 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 108091026805 miR-10 stem-loop Proteins 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 201000003956 middle ear cancer Diseases 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 230000001400 myeloablative effect Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 108020001162 nitroreductase Proteins 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000002747 omentum Anatomy 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 201000008006 pharynx cancer Diseases 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 201000003437 pleural cancer Diseases 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000005737 synergistic response Effects 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 230000009258 tissue cross reactivity Effects 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
• PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 201000011294 ureter cancer Diseases 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000012130 whole-cell lysate Substances 0.000 description 1
• WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1